Sector News

Valeant posts 36% growth amid pricing scrutiny; may sell neurology biz

October 19, 2015
Life sciences

Valeant may be the subject of current government scrutiny, and it may have recently suffered a stock-price freefall. But the company gave investors some good news Monday with earnings that beat their mark.

The Canadian drugmaker recorded third-quarter EPS of $2.74, excluding one-time items–topping consensus estimates of $2.70. Revenue also ticked upward by 36% year-over-year, hitting $2.79 billion, partly thanks to recent acquisition Salix, which delivered $461 million–almost 50% more than the $300 million Valeant had forecast.

And another high point for the Quebec-based pharma: The growth was more volume than price, if by a small margin. Evercore ISI analyst Umer Raffat noted that in the U.S., 19% of Valeant’s branded prescription product growth was driven by volume increases, compared with 15% from price increases.

Those price increases have put Valeant in the hot seat recently, with lawmakers demanding information on the company’s strategy, particularly on a couple of large–and highly publicized–increases. Last week, Valeant revealed that it had received subpoenas from the U.S. Attorney’s Office for the District of Massachusetts and from the U.S. Attorney’s Office for the Southern District of New York, requesting materials largely related to its pricing decisions.

CEO J. Michael Pearson has maintained that hiking prices–which Valeant has done 56 times this year alone–isn’t a key facet of the company’s broader strategy. As he outlined Monday on a conference call, the company has other moves up its sleeve to keep business booming.

For one, it may hive off its neurology and “other” drugs business, he told investors, a non-core unit that would make up about 10% of future sales.

“Given the current environment, I think that it probably doesn’t make sense for us to hold on to it,” he said, as quoted by Bloomberg. “Hopefully we’ll figure out a way to do it in a way that shareholders can continue to participate in an entity that’s maybe not a growth company, but a big dividend company.”

Valeant also plans to sock more money into R&D, an area where it’s traditionally been averse to spending. Instead, it’s thrown its weight behind acquisitions–and it’ll continue to do so, though with different criteria.

“It’s likely we’ll pursue fewer if any transactions that are focused on mispriced products,” Pearson said on the call.

Instead, the company will be seeking “durable” assets that would fit with its Bausch + Lomb eyecare business, which it picked up back in 2013, Reuters reports.

In the meantime, Valeant expects sales to keep expanding. It raised its Q4 forecast slightly, to a range of $3.25 billion to $3.45 billion, up from $3.2 billion to $3.4 billion. On the adjusted EPS side, the company now predicts it’ll land between $4 to $4.20, boundaries it ticked upward from an earlier $3.98 to $4.18 forecast.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend